VSee Health, Inc. Schedule 13G/A reports that Armistice Capital, LLC and Steven Boyd together beneficially own 4,861,392 shares, representing 9.99% of the outstanding common stock. The filing states Armistice Capital shares voting and dispositive power over those shares through its role as investment manager of Armistice Capital Master Fund Ltd.
The statement explains the Master Fund is the direct holder and that the Master Fund "specifically disclaims beneficial ownership" by reason of its inability to vote or dispose under its Investment Management Agreement. The amendment is signed by Steven Boyd on 05/15/2026.
VSee Health, Inc. files its annual report describing a telehealth software platform and high-acuity critical care services alongside significant losses and going‑concern risks. The company reported operating losses of $9,582,893 in 2025 and $62,150,845 in 2024, with an accumulated deficit of $82,416,723 as of December 31, 2025. Its auditor highlighted substantial doubt about VSee’s ability to continue as a going concern due to ongoing losses and negative operating cash flows.
VSee delivers configurable, no‑code and low‑code telehealth tools through VSee Lab and tele‑ICU and specialty physician services through iDoc, targeting hospital systems, ICUs, correctional facilities and other high‑acuity settings. Competition is intense from large telehealth vendors, EMR‑embedded tools and in‑house solutions. The company faces heavy regulatory exposure, including HIPAA, state privacy rules, anti‑kickback and self‑referral laws, False Claims Act risk and evolving Medicare/Medicaid telehealth reimbursement. VSee also depends heavily on a small number of major customers and approximately 93 board‑certified physicians within a 209‑person workforce.
Leonard Jerry reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. Chief Financial Officer Leonard Jerry received multiple grants of common stock as equity compensation. On March 23, 2026, he was awarded grants including 66,845 shares at $0.37, 40,984 shares at $0.61, 21,552 shares at $1.16, and 20,833 shares at $1.20 per share.
Footnotes explain these shares were issued under the 2024 Incentive Plan as quarterly equity awards owed for the quarters ended March 31, June 30, September 30, and December 31, 2025, with each grant amount based on the common stock closing price on the respective quarter-end date.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.
VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.
Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at $0.3200 per share and 105,251 shares at $0.6500 per share through derivative conversions.
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSee Health, Inc. Schedule 13G/A discloses that the reporting persons beneficially own 833,331 shares, representing 2.0% of the class. The reported position consists of Public Warrants to purchase 702,896 shares plus 130,435 shares issuable under a Warrant Exchange Agreement. The percentage calculation references 40,230,845 shares outstanding as of February 2, 2026, plus the 833,331 issuable shares.
VSee Health, Inc. entered a managed services agreement with GoMyRx, Inc. under which VSee will provide platform administration, customer support, vendor coordination, and reporting services. VSee will bill GoMyRx monthly for actual expenses plus a 10% markup, and the agreement runs through December 26, 2027, with optional month-to-month extensions for six months.
Separately, VSee agreed to purchase $2.0 million of GoMyRx common stock from Go Biz Holdings, LLC in a private transaction, representing a 10% ownership stake in GoMyRx. The shares are restricted securities issued under Section 4(a)(2) and Rule 506 of Regulation D.